DrugPatentWatch Database Preview
Drugs in Development Information for Dacetuzumab
What is the drug development status for Dacetuzumab?
Dacetuzumab is an investigational drug.
There have been 7 clinical trials for Dacetuzumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2006.
The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Lymphoma, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Seattle Genetics, Inc., Genentech, Inc., and [disabled in preview].
Summary for Dacetuzumab
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2006-12-01) |
| Vendors | 0 |
Recent Clinical Trials for Dacetuzumab
| Title | Sponsor | Phase |
|---|---|---|
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | Genentech, Inc. | Phase 1 |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | Seattle Genetics, Inc. | Phase 1 |
| A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | Genentech, Inc. | Phase 2 |
Clinical Trial Summary for Dacetuzumab
Top disease conditions for Dacetuzumab
Top clinical trial sponsors for Dacetuzumab
US Patents for Dacetuzumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
